KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Sí 79%
Calidad del mercado
43 / 100
Baja calidadVolumen 24h
—
Liquidez
437,2 €
Baja liquidezCompra / Venta
78.0% / 84.0%
Spread
6.0 pt
Spread amplioDatos de mercado
Actualizado hace 7 minutos
17 jun 26, 21:00 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiEbola pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketNew pandemic in 2026?
PolymarketReglas
If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida mediante:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact.
- It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme.
- Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.
Mercados abiertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 18,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volumen total
- 1,6 M €
- Volumen 24h
- 5,2 mil €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 resultados más
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volumen total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volumen total
- 916 mil €
- Volumen 24h
- 1,5 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 resultados más
- Volumen total
- 863,6 mil €
- Volumen 24h
- 1 mil €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de FDA decision: Venglustat by Sanofi (in 2026)?
- Kalshi cotiza Yes al 79% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve FDA decision: Venglustat by Sanofi (in 2026)?
- Está previsto que FDA decision: Venglustat by Sanofi (in 2026) se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida FDA decision: Venglustat by Sanofi (in 2026)?
- Kalshi liquida este mercado del siguiente modo: If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.